Blake Cover, MD
Family Medicine · Omaha, NENPI 1225484934
Payments from drug & device makers
Across 195 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$441
- AbbVie$411
- Lilly USA, LLC$258
- Otsuka America Pharmaceutical, Inc.$232
- Teva Pharmaceuticals USA, Inc.$213
- AstraZeneca$206
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $441 |
| AbbVie(2 entities) | 29 | $411 |
| Lilly USA, LLC | 19 | $258 |
| Otsuka America Pharmaceutical, Inc. | 12 | $232 |
| Teva Pharmaceuticals USA, Inc. | 15 | $213 |
| AstraZeneca | 14 | $206 |
| Amgen | 10 | $153 |
| Sanofi-aventis U.S. LLC | 8 | $119 |
| Dexcom, Inc. | 6 | $89 |
| Astellas Pharma US Inc | 5 | $84 |
| Medtronic | 3 | $80 |
| Neurocrine Biosciences, Inc. | 3 | $69 |
| Novartis | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Boehringer Ingelheim | 4 | $59 |
| Merck | 4 | $58 |
| Bayer | 3 | $49 |
| Boston Scientific | 2 | $47 |
| GSK | 3 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Alkermes, Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $32 |
| Vertex | 2 | $30 |
| Abbott | 1 | $25 |
| Viatris Specialty LLC | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Intuitive Surgical | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Indivior Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$124
How this compares
$3,112 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $111,758 |
| JardianceEmpagliflozin | 163 | $97,155 |
| FarxigaDapagliflozin Propanediol | 116 | $73,806 |
| OzempicSemaglutide | 70 | $70,672 |
| IngrezzaValbenazine Tosylate | 11 | $64,458 |
| MounjaroTirzepatide | 51 | $59,652 |
| TrulicityDulaglutide | 60 | $58,121 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $47,552 |
| XareltoRivaroxaban | 74 | $46,928 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $35,636 |
| JanuviaSitagliptin Phosphate | 78 | $34,454 |
| RybelsusSemaglutide | 32 | $32,195 |
| MyrbetriqMirabegron | 37 | $16,009 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $15,765 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 14 | $11,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Trijardy Xr, Synjardy Xr, Tradjenta | $59 | $140,679229 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $258 | $120,576157 claims |
| PfizerEliquis, Abrysvo | $14 | $115,879206 claims |
| Novo NordiskOzempic, Rybelsus | $441 | $102,867102 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $42 | $85,861158 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $206 | $81,403128 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $69 | $64,45811 claims |
| Johnson & JohnsonXarelto | $32 | $46,92874 claims |
| MerckJanuvia | $58 | $34,45478 claims |
| AbbVieVraylar, Linzess, Lumigan | $411 | $18,69539 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $16,00937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Kenneth BladOmaha$1.6M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
- Gregston NelsonOmaha$147K
- Birgit KhandalavalaOmaha$107K
- John HallgrenOmaha$94K
- Gerard StanleyOmaha$50K
- Kent JohnsonOmaha$16K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.